Skip to content
Dimethyl sulfoxide
Rimso (dimethyl sulfoxide) is a small molecule pharmaceutical. Dimethyl sulfoxide was first approved as Rimso-50 on 1982-01-01. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 2 and dual specificity mitogen-activated protein kinase kinase 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Rimso
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dimethyl sulfoxide
Tradename
Company
Number
Date
Products
RIMSO-50MylanN-017788 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
rimso-50New Drug Application2021-03-17
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BX: Other urologicals in atc
— G04BX13: Dimethyl sulfoxide
M: Musculo-skeletal system drugs
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AX: Other topical products for joint and muscular pain in atc
— M02AX03: Dimethyl sulfoxide
HCPCS
Code
Description
J1212
Injection, dmso, dimethyl sulfoxide, 50%, 50 ml
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Interstitial cystitisD018856EFO_1000869N30.1—1—1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545321——4
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.0—4———4
LymphomaD008223C85.9—4———4
Overactive urinary bladderD053201EFO_1000781N32.8111———1
GlioblastomaD005909EFO_0000515—1———1
GliomaD005910EFO_0000520—1———1
AstrocytomaD001254EFO_0000271—1———1
Erdheim-chester diseaseD031249—1———1
Urinary bladder diseasesD001745N32.9—1———1
Breast neoplasmsD001943EFO_0003869C50—1———1
RadiodermatitisD011855L58—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomatognathic diseasesD009057K08.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDIMETHYL SULFOXIDE
INNdimethyl sulfoxide
Description
Dimethyl sulfoxide is a 2-carbon sulfoxide in which the sulfur atom has two methyl substituents. It has a role as a polar aprotic solvent, a radical scavenger, a non-narcotic analgesic, an antidote, a MRI contrast agent, an Escherichia coli metabolite, a geroprotector and an alkylating agent. It is a sulfoxide and a volatile organic compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[S+](C)[O-]
Identifiers
PDB—
CAS-ID67-68-5
RxCUI3455
ChEMBL IDCHEMBL504
ChEBI ID28262
PubChem CID679
DrugBankDB01093
UNII IDYOW8V9698H (ChemIDplus, GSRS)
Target
Agency Approved
MAP2K2
MAP2K2
MAP2K1
MAP2K1
Organism
Homo sapiens
Gene name
MAP2K2
Gene synonyms
MEK2, MKK2, PRKMK2
NCBI Gene ID
5605
Protein name
dual specificity mitogen-activated protein kinase kinase 2
Protein synonyms
ERK activator kinase 2, MAP kinase kinase 2, MAPK/ERK kinase 2, MEK 2, mitogen-activated protein kinase kinase 2, p45
Uniprot ID
P36507
Mouse ortholog
Map2k2 (26396)
dual specificity mitogen-activated protein kinase kinase 2 (Q9D7B0)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 162,126 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,641 adverse events reported
View more details